Trial Profile
Phase I trial of INT 767 in healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2016
Price :
$35
*
At a glance
- Drugs INT 767 (Primary)
- Indications Diabetic nephropathies; Hepatic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- 04 Aug 2016 According to an Intercept Pharmaceuticals media release, the company expects to complete this trial by end of the year 2016.
- 05 May 2016 According to an Intercept Pharmaceuticals media release, the company expects to complete this trial in second half of 2016.
- 30 Nov 2015 Status changed from planning to recruiting, according to an Intercept Pharmaceuticals media release.